Cryo-Cell InternationalSTU:ZCY +17.80%58 ROA % is 0.31% as of Feb. 2026, which is 86% below its 10-year median of 2.27. GuruFocus rates STU:ZCY with a GF Score™ of 58/100 and a GF Value™ of €4.98 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 684 Healthcare Providers & Services companies, Cryo-Cell International ranks worse than 72.81% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Cryo-Cell International's annualizedNet Income for the quarter that ended in Feb. 2026 was €0.16 Mil.
Cryo-Cell International's average Total Assets over the quarter that ended in Feb. 2026 was €52.45 Mil. Therefore, Cryo-Cell International's annualized ROA % for the quarter that ended in Feb. 2026 was 0.31%.
The historical rank and industry rank for Cryo-Cell International's ROA % or its related term are showing as below:
STU:ZCY'
s ROA % Range Over the Past 10 Years
Min: -15.1 Med: 2.27 Max: 10.66
Current: -4.24
During the past 13 years, Cryo-Cell International's highest ROA % was 10.66%. The lowest was -15.10%. And the median was 2.27%.
STU:ZCY's ROA % is ranked worse than 72.81% of 684
companies
in the Healthcare Providers & Services industry
Industry Median: 1.78
vs STU:ZCY: -4.24
Cryo-Cell International (STU:ZCY) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Feb. 2026) net income data. The Revenue data used here is four times the quarterly (Feb. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Cryo-Cell International's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryo-Cell International ROA % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's ROA % distribution charts can be found below:
* The bar in red indicates where Cryo-Cell International's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Feb. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Cryo-Cell International (STU:ZCY) has a ROA % of 0.31% as of Feb. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Cryo-Cell International and its competitors. This is 86% below median its historical median of 2.27. According to the industry distribution chart, Cryo-Cell International ranks #498 out of 684 companies in the Healthcare Providers & Services industry, placing it in the top 72.8%.
Is Cryo-Cell International's ROA % too high?
Cryo-Cell International's current ROA % of 0.31% is 86% below median its 10-year median of 2.27. The Healthcare Providers & Services industry median ROA % is 1.78. Cryo-Cell International's value of 0.31% is 82.6% below this industry median. Based on the distribution chart, Cryo-Cell International ranks #498 out of 684 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Cryo-Cell International has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's ROA % compare to CCM and CDIX?
According to the Healthcare Providers & Services industry distribution chart, Cryo-Cell International ranks #498 out of 684 companies for ROA %. This places Cryo-Cell International in the lower half of its industry. The industry median ROA % is 1.78. Cryo-Cell International's value of 0.31% is 82.6% below this benchmark. While the company's 10-year median is 2.27 vs. the industry median of 1.78, Cryo-Cell International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Healthcare Providers & Services company?
The median ROA % among Healthcare Providers & Services companies is 1.78, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryo-Cell International's current ROA % of 0.31% is 82.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Cryo-Cell International and its competitors. For the Healthcare Providers & Services industry, the median ROA % is 1.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryo-Cell International's current ROA % is 0.31%, which is 86% below median its own 10-year median of 2.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (STU:ZCY) is currently considered Possible Value Trap. The stock's GF Value™ is €4.98, compared to a current price of €2.78 — trading 44.2% below its estimated fair value. The current ROA % is 0.31%, which is 86% below median its 10-year median of 2.27 and 82.6% below the Healthcare Providers & Services industry median of 1.78. Cryo-Cell International's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Cryo-Cell International (STU:ZCY), the current ROA % is 0.31% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryo-Cell International (STU:ZCY) Overvalued in 2026?
Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued.
The current stock price of €2.78 is trading 44.2% below its estimated GF Value™ of €4.98.
GuruFocus considers Cryo-Cell International to be Possible Value Trap.
Key valuation signals for STU:ZCY:
ROA %: 0.31% (86% below median its 10-year median of 2.27)
GF Value™: €4.98 vs. price of €2.78 (44.2% below fair value)
Industry Position: 82.6% below the Healthcare Providers & Services median (#498 of 684)
No single metric tells the full story. See the STU:ZCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
58GF Score
Get the complete analysis for STU:ZCY
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:ZCY has been successfully added to your 
